103441-69-6

Basic information

• Product Name: 6-aMino-3,4-dihydro-2H-chroMen-2-one
• Synonyms: 6-aMino-2,3-dihydro-4H-chroMen-4-one;6-aMino-3,4-dihydro-2H-chroMen-2-one;6-AMinochroMan-4-one;6-AMinochroManone;6-AMINO-3,4-DIHYDRO-2H-1-BENZOPYRAN-4-ONE
• CAS NO: 103441-69-6
• Molecular Formula: C₉H₉NO₂
• Molecular Weight: 163.17326
• Mol File: 103441-69-6.mol

Chemical Properties

• Boiling Point: 379.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.294±0.06 g/cm3(Predicted)
• PKA: 4.04±0.20(Predicted)
• CAS DataBase Reference: 6-aMino-3,4-dihydro-2H-chroMen-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-aMino-3,4-dihydro-2H-chroMen-2-one(103441-69-6)
• EPA Substance Registry System: 6-aMino-3,4-dihydro-2H-chroMen-2-one(103441-69-6)

Safety Data

• Hazardous Substances Data: 103441-69-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-aMino-3,4-dihydro-2H-chroMen-2-one is used as a potential therapeutic agent for the treatment of various medical conditions due to its antioxidant, anti-inflammatory, and anti-cancer properties. Its ability to modulate cellular signaling pathways and gene expression makes it a valuable compound for drug development.
Used in Research Applications:
In the field of scientific research, 6-aMino-3,4-dihydro-2H-chroMen-2-one serves as a subject of study for understanding its pharmacological activity and potential use in treating different diseases. Its role in biological processes and interaction with cellular mechanisms is of interest to researchers working on drug discovery and development.

Upstream product

• 68043-53-8 6-nitrochroman-4-one 
• 100-02-7 4-nitro-phenol 
• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 
• 10572-16-4 3-(4-nitrophenoxy)propanoic acid 

Downstream Products

• 1392810-22-8 R/S-N-2-chlorophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2H-1-benzopyran-4-yl)urea 

Relevant articles and documents

Structurally-thrifty and visible-absorbing fluorophores

Fluorophores with a minimal push-pull backbone are actively pursued due to their potentials in biological labelling. Herein a series of structurally-thrifty and visible-absorbing fluorophores (SDXs) were successfully constructed following the D′D-π-A design strategy, in which a secondary donor (D′) was introduced in conjugation with the donor (D) to enhance its electron donating capability. For a very small scaffold, SDXs exhibit a surprisingly long-wavelength absorption band in the visible spectral range (λabs = 420 nm) and a strong green fluorescence emission (λem = 530 nm) with a fluorescence quantum yield up to 0.84. Notably, fluorescence of SDXs was quenched in hydrogen-bonding solvents, e.g. MeOH and H2O. This phenomenon renders SDXs feasibility for imaging of cellular non-hydrogen-bonding microenvironment, as demonstrated with BEAS-2B cells. These results proved that the D′D-π-A is a powerful design strategy to construct novel structurally-thrifty fluorophores.

ROR-GAMMA MODULATORS AND USES THEREOF

The present invention relates to a compound of formula I, or an isotopic form, stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparation. The invention further relates to pharmaceutical compositions containing the compounds and their use in the treatment of diseases or disorders mediated by RORγ.

Dihydrobenzopyran, thiochroman, tetrahydroquinoleine and tetrahydronaphthalene derivatives and their use in anti-cancer therapy

New dihydrobenzopyran, thiochroman, tetrahydroquinoleine and tetrahydronaphthalene derivatives and their use in anti-cancer therapy with the general formula :

DIHYDROBENZOPYRAN, THIOCHROMAN, TETRAHYDROQUINOLEINE AND TETRAHYDRONAPHTALENE DERIVATIVES AND THEIR USE IN ANTICANCER THERAPY

New dihydrobenzopyran, thiochroman, tetrahydroquinoleine and tetrahydronaphthalene derivatives and their use in anti-cancer therapy with the general formula (I).

SPIROAMINODIHYDROTHIAZINE DERIVATIVES

A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer- type dementia.

PIPERIDINYLCHROMEN-6-YLSULFONAMIDE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS

The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a CNS disorder relating to or affected by the 5-HT6 receptor.

Preparation of 6-substituted 4-chromanones

Disclosed is a practical and efficient process for preparing 6-substituted 4-chromanones from phenolic acrylate ester compounds derivable from para-substituted phenolic or thiophenolic compounds and beta-unsubstituted acrylic acid compounds which are esterifiable therewith. The process includes effecting rearrangement of a phenolic or thiophenolic acrylate ester in the presence of a rearrangement effective amount of hydrogen fluoride to the corresponding hydroxy - or mercapto (vinyl ketone) wherein the carbonyl carbon atom of the vinyl carboxy group is directly attached to the benzene ring ortho to the hydroxy or mercapto group. Thereafter, the vinyl ketone is cyclized to the corresponding 6-substituted 4-chromanone in the presence of a cyclization-effective amount of hydrogen fluoride. The 6-substituted 4-chromanones prepared by the process are useful as intermediates for preparing pharmaceutical agents.